Sign in
TerminatedPhase 3

Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)

Key facts

Who runs it
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Where
Spain12 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
14 people enrolled
Started
10 Jul 2024
Ended
6 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metoprolol Injection
  • saline 0.9%
Record updated
2 June 2026
Why it stopped
Persistently low recruitment of subjects

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patients (≥18 years and <80 years) with a clinical diagnosis of ARDS of any aetiology (pneumonia, including SARS-CoV-2, sepsis, pancreatitis, bronchospasm and trauma) admitted to the ICU
  • Orotracheal intubation (OTI) and mechanical ventilation within 72 hours prior to randomisation
  • Moderate-severe ARDS (PaO2/FiO2: ≤200 mmHg under standardised conditions (PEEP≥5 cm H2O)
  • Heart rate ≥ 60 bpm
  • Invasive systolic blood pressure ≥ 110 mmHg

Who cannot take part

  • Prolonged hospital admission prior to randomisation (i.e. ≥7 days at the time of randomisation)
  • Concomitant acute heart failure (cardiac index ≤2.5 L/m2 or pulmonary capillary pressure ≥15 mmHg or clinical suspicion)
  • Concomitant pulmonary embolism
  • Known asthma before admission (with active bronchodilator therapy)
  • Active beta-blocker treatment prior to admission (i.e. within 3 months prior to admission)
  • Life expectancy due to other processes (cancer, degenerative diseases, etc.) of less than 6 months
  • Second-degree atrioventricular (AV) block, 2:1 AV block, high-grade/advanced AV block and third-degree AV block. Also significant sinus bradycardia, which would be implied by having a heart rate >60 bpm as an inclusion criterion
  • Known severe peripheral arterial disease
  • Reduced left ventricular ejection fraction (LVEF <50%)
  • Right ventricular (RV) systolic dysfunction
  • Pregnant or breastfeeding women
  • Cardiogenic shock
  • Persistent invasive blood pressure <110 mmHg despite vasopressor agents
  • Use of noradrenaline at concentrations greater than 0.2 µg/kg/min at the time of the randomisation
  • Use of dobutamine within 48 hours before randomisation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Respiratory Distress Syndrome (ARDS).

The 2 groups in the trial

  • MetoprololExisting treatment, for comparison

    Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.

    Treatment: Metoprolol Injection

  • SalinePlacebo, for comparison

    Participants will be administered IV saline (0.9% sodium chloride) (3 ampoules of 5 ml) diluted in 100 ml of saline.

    Treatment: saline 0.9%

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the to Assess the Efficacy of Intravenous Metoprolol in Patients With Acute Respiratory Distress Syndrome (ARDS).
Record updated
2 June 2026